Ardelyx Q3 2026 net loss narrows 24% to $737,000

Bitget2026/11/03 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ardelyx’s third-quarter 2026 net loss narrowed 24% year-over-year to $737,000.
Product revenue rose 19% year-over-year to $125.5 million; IBSRELA revenue climbed 23% to $96.3 million.
The Phase 3 ACCEL trial completed enrollment ahead of schedule, with topline data expected in the second half of 2027.
Full-year 2026 revenue guidance remained $350 million–$370 million for IBSRELA and $110 million–$120 million for XPHOZAH.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031601PRIMZONEFULLFEED9869383) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ardelyx Q3 2026 net loss narrows 24% to $737,000

You may also like

Crypto prices